Literature DB >> 1758174

Chylomicrons can inhibit endotoxin activity in vitro.

E B Eichbaum1, H W Harris, J P Kane, J H Rapp.   

Abstract

Trauma, thermal injury, and nonlethal doses of endotoxin can promote the translocation of endotoxin across the mucosal barrier of the colon into the mesenteric lymphatics and systemic circulation. Bacterial endotoxemia induces changes in lipid metabolism, including an increase in circulating triglyceride-rich lipoproteins. Because cholesterol-rich lipoproteins can neutralize the toxic activity of endotoxin, both in vitro and in vivo, we asked whether triglyceride-rich chylomicrons can inhibit endotoxin activity in vitro as measured by a chromogenic Limulus assay. We tested the effect of intact versus heat-denatured chylomicrons on the in vitro activity of increasing concentrations of Escherichia coli (055:B5) endotoxin. Intact chylomicrons inhibited up to 12-fold the detection of as much as 1 microgram of endotoxin/mg of chylomicron triglyceride, compared to denatured chylomicrons (P less than 0.001). This study shows that chylomicrons are potent inhibitors of endotoxin activity in vitro. Because translocated endotoxin from the colon associates with gut-derived chylomicrons in the mesenteric lymphatics, this may represent a natural defensive mechanism against endotoxemia of enteric origin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1758174     DOI: 10.1016/0022-4804(91)90143-a

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  18 in total

1.  Distribution of bacterial endotoxin in human and rabbit blood and effects of stroma-free hemoglobin.

Authors:  R I Roth; F C Levin; J Levin
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

2.  Plasma levels of soluble CD14 independently predict mortality in HIV infection.

Authors:  Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek
Journal:  J Infect Dis       Date:  2011-01-20       Impact factor: 5.226

3.  Effect of hypertriglyceridemia on endotoxin responsiveness in humans.

Authors:  T van der Poll; C C Braxton; S M Coyle; M A Boermeester; J C Wang; P M Jansen; W J Montegut; S E Calvano; C E Hack; S F Lowry
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

Review 4.  NKT cells in sepsis.

Authors:  Briana Leung; Hobart W Harris
Journal:  Clin Dev Immunol       Date:  2010-10-04

Review 5.  Microbial translocation in HIV infection: causes, consequences and treatment opportunities.

Authors:  Netanya G Sandler; Daniel C Douek
Journal:  Nat Rev Microbiol       Date:  2012-08-13       Impact factor: 60.633

Review 6.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

7.  Chylomicrons enhance endotoxin excretion in bile.

Authors:  T E Read; H W Harris; C Grunfeld; K R Feingold; M C Calhoun; J P Kane; J H Rapp
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

8.  Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death.

Authors:  H W Harris; C Grunfeld; K R Feingold; T E Read; J P Kane; A L Jones; E B Eichbaum; G F Bland; J H Rapp
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

9.  Increased inflammation, impaired bacterial clearance, and metabolic disruption after gram-negative sepsis in Mkp-1-deficient mice.

Authors:  W Joshua Frazier; Xianxi Wang; Lyn M Wancket; Xiang-An Li; Xiaomei Meng; Leif D Nelin; Andrew C B Cato; Yusen Liu
Journal:  J Immunol       Date:  2009-11-04       Impact factor: 5.422

10.  Chronic immune activation in common variable immunodeficiency (CVID) is associated with elevated serum levels of soluble CD14 and CD25 but not endotoxaemia.

Authors:  J Litzman; J Nechvatalova; J Xu; O Ticha; M Vlkova; Z Hel
Journal:  Clin Exp Immunol       Date:  2012-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.